Recipharm and Sanofi have signed an agreement to transfer the Holmes Chapel site in the United Kingdom from Sanofi to CDMO Recipharm. “Holmes Chapel brings Recipharm an ideal opportunity to accelerate its offering to customers with access to novel respiratory products,” said Thomas Eldered, CEO of Recipharm. “As an already successful CMO with several clients, we look forward to…
Recipharm Invests In Brexit Preparations
Recipharm, the contract development and manufacturing organization (CDMO), has established a dedicated taskforce to manage the potential impact of Brexit on its organization. With less than a year until the U.K. exits the European Union (EU), the Sweden headquartered global CDMO is focused on managing the transition with minimal impact to its operations and customers.…
CDMO Recipharm Collaboration To Focus On Novel Drug Delivery Technologies
Recipharm, a contract development and manufacturing organization (CDMO), has signed a licensing agreement with Altus Formulation Inc., a Canadian drug development company, to allow its customers to access new drug delivery technologies and products. Under the terms of the agreement, Recipharm will co-develop new value added medicines for its customers utilizing Altus’ patented Intellitab and Flexitab drug delivery…
CDMO Recipharm Appoints President Of Development Services
Contract development and manufacturing organization (CDMO) Recipharm has appointed Bernard Pluta to lead its new global development organization. The newly established position forms part of the ongoing transformation of Recipharm’s Development Services, in which a total of 400 employees across six countries are united to deliver a comprehensive development offering. The scientific, chemical, and pharmaceutical expertise will cover…
CDMO Recipharm Equips Three More Facilities For U.S. Serialization
Recipharm, a contract development and manufacturing organization (CDMO), announced Monday that it has equipped three more of its facilities with serialization capabilities in line with the U.S. regulatory requirements under the November 27 introduction of the Drug Supply Chain Security Act (DSCSA). The facilities in Brescia, Italy and Karlskoga and Uppsala, Sweden, are the latest of Recipharm’s sites to be…
Recipharm Opens New GMP Suite for Clinical Trial Material
CDMO Recipharm Delivers First Serialized Batch to Saudi Arabia
CDMO Recipharm Partners with Sato to Manufacture Product for Japanese Market
CDMO Recipharm Completes Strategic Acquisition in India
Recipharm AB Acquires Nitin Lifesciences
Recipharm AB has completed the acquisition of a majority stake in Nitin Lifesciences Limited, an Indian sterile injectables CMO, currently owned by the Sobti family. Recipharm has acquired 74 percent of the shares for a purchase consideration of INR 6,713 million (SEK 824 million) on a cash and debt free basis. Thomas Eldered, CEO of…